Education
About Us
Working with TipRanks
Follow Us
Strata Critical Medical, Inc. (SRTA)
NASDAQ:SRTA
Earnings Data
Report Date
May 12, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.02Last Year’s EPS
-0.04Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and financial improvement driven by robust organic logistics growth (35%+), a successful integration of the Keystone acquisition, significant gross profit and adjusted EBITDA improvement, and raised 2026 guidance. Key positives include no debt, a healthy cash balance (~$61M), an active M&A pipeline supported by an undrawn $30M facility, and regulatory trends that favor the company's DCD/NRP capabilities. Near-term weaknesses are largely execution and timing-related: a negative operating cash flow in Q4 driven by nonrecurring charges and working capital build from integration, a discrete aircraft corrosion/write-down, elevated SG&A from Keystone, and an anticipated sequential margin dip in Q1 due to mix and weather. Overall, the positives (sizable growth, margin improvement, guidance raises, strong balance sheet and strategic positioning) substantially outweigh the transient and integration-related lowlights.Company Guidance
Strong Organic and Logistics Growth
Q4 logistics (organic) revenue grew 35.3% year-over-year to $49.2M (prior-year $36.4M). Company cited organic growth of ~35% in Q4 overall, driving a strong quarterly performance and sustained volume into 2026.
Full-Year Results Beat Guidance
Full-year 2025 revenue of $197.1M and adjusted EBITDA of $14.1M both beat the high end of prior guidance ranges, supported by the strong Q4 performance.
Material Improvement in Profitability Metrics
Q4 gross profit increased 90% to $14.4M versus $7.6M prior-year; blended gross margin improved ~80 basis points to 21.6% from 20.8%. Logistics gross profit rose 39.5% to $10.6M with a ~70-basis-point improvement in logistics gross margin to 21.5%.
Adjusted EBITDA Recovery and Margin Expansion
Adjusted EBITDA increased to $7.0M in Q4 2025 (from $1.1M year-ago and $4.2M last quarter). Q4 adjusted EBITDA margin was 10.4%, and company raised 2026 adjusted EBITDA guidance to $29–$33M (from $28–$32M).
Upgraded 2026 Revenue Guidance and Strong Cash Position
2026 revenue guidance raised to $260–$275M (from $255–$270M). Company ended Q4 with no debt and approximately $61.0M of cash and short-term investments, and reiterated free cash flow before aircraft/engine purchases guidance of $15–$22M.
Successful Keystone Integration and Strategic M&A Platform
First full quarter post-Keystone close produced $17.6M of clinical revenue in Q4 (transplant clinical $7.8M; other clinical $9.8M). Management expects continued M&A to accelerate adjusted EBITDA growth at least 30% annually and closed a $30M asset-based credit facility (undrawn, expandable to $50M) to support acquisitions.
Regulatory Tailwinds and Service Differentiation
Proposed CMS/OPTN actions (incentives for DCD donors, continuous distribution momentum for lungs) align with the company's capabilities (NRP and DCD expertise). Approximately 20% of revenue is from OPOs; Tier 1 OPO customers represent 2.4x the revenue of Tier 3 OPOs. Recent decertification/absorption of an underperforming OPO directly led to new business.
Fleet Strategy Produces Business Benefits
Company maintains an asset-light model complemented by ~30 dedicated/owned aircraft. Owning a small portion of capacity unlocked new business, aided negotiations with third-party carriers, and management plans to add ~two owned aircraft in 2026 to support new geographies; one aircraft already acquired in Q1 and in conformity process.
SRTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SRTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $4.49 | $4.80 | +6.90% |
Nov 10, 2025 | $4.43 | $4.85 | +9.48% |
Aug 05, 2025 | $4.43 | $4.16 | -6.09% |
May 12, 2025 | $2.92 | $3.46 | +18.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Strata Critical Medical, Inc. (SRTA) report earnings?
Strata Critical Medical, Inc. (SRTA) is schdueled to report earning on May 12, 2026, After Close (Confirmed).
What is Strata Critical Medical, Inc. (SRTA) earnings time?
Strata Critical Medical, Inc. (SRTA) earnings time is at May 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRTA EPS forecast?
SRTA EPS forecast for the fiscal quarter 2026 (Q1) is 0.02.